435273-49-7

Basic information

• Product Name: 2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97%
• Synonyms: 2-broMo-1-(3-broMo-4-fluorophenyl)ethanone;2-Bromo-1-(3-bromo-4-fluorophenyl)ethan-1-one, 2,3'-Dibromo-4'-fluoroacetophenone;2,3'-Dibromo-4'-fluoroacetophenone 97%
• CAS NO: 435273-49-7
• Molecular Formula: C₈H₅Br₂FO
• Molecular Weight: 295.93
• Mol File: 435273-49-7.mol

Chemical Properties

• Melting Point: 48-52 °C
• Boiling Point: 300.2°C at 760 mmHg
• Flash Point: 110 °C
• Appearance: /
• Density: 2.042g/cm³
• Vapor Pressure: 0.00114mmHg at 25°C
• Refractive Index: 1.597
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97%(435273-49-7)
• EPA Substance Registry System: 2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97%(435273-49-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• RIDADR: UN 3335
• WGK Germany: 3
• Hazardous Substances Data: 435273-49-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97% is used as an intermediate in pharmaceutical research for the production of various pharmaceutical drugs and fine chemicals. Its unique structure and reactivity make it a valuable compound for synthesizing complex molecules and pharmaceutical compounds.
Used in Organic Synthesis:
2,3'-DIBROMO-4'-FLUOROACETOPHENONE, 97% is used as a key intermediate in organic synthesis for the production of various fine chemicals. Its high purity ensures consistency and reliability in reactions and processes, making it an ideal choice for research and industrial applications.

InChI:InChI=1/C7H3Br2FO/c8-6-4(7(9)11)2-1-3-5(6)10/h1-3H

Upstream product

• 1007-15-4 4-fluoro-3-bromoacetophenone 

Downstream Products

• 929884-59-3 C₁₀H₇BrFNS 
• 929884-51-5 C₉H₈BrFO 

Relevant articles and documents

An umpolung oxa-[2,3] sigmatropic rearrangement employing arynes for the synthesis of functionalized enol ethers

An oxa-[2,3] sigmatropic rearrangement involving arynes is reported featuring the umpolung of ketones, where the C=O bond polarity is reversed. The in situ-generated sulfur ylides from β-keto thioethers and arynes undergo efficient rearrangement allowing the facile and robust synthesis of functionalized enol ethers in high yields and excellent functional group compatibility. Preliminary mechanistic studies rule out the possibility of Pummerer-type rearrangement operating in this case.

Substituted imidazole-1-vinyl compound and use thereof

The invention relates to a substituted imidazole-1-ethylene compound as well as a preparation and an application thereof. The substituted imidazole-1-ethylene compound is a compound shown as a formula I, or salts thereof formed with medicinal acids or bases. According to the antifungal activity test performed on eight clinical fungi by the compound provided in the invention, a good fungus killing effect is achieved. The compound can serve as a novel broad-spectrum antifungal activity compound and is developed into antifungal medicines, disinfectants or feed additives.

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.